Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9479399 | 0.80 | TLR8 (0.41) | LMNASMN1; SMN2ALOX15POLBALDH1A1 | |
| SCHEMBL9479380 | 0.80 | KCNH2 (0.36) | LMNAHPGDSMN1; SMN2ALOX15POLB | |
| SCHEMBL442375 | 0.80 | MPO (0.43) | SMN1; SMN2MAPTHTT | |
| SCHEMBL9479332 | 0.78 | TLR8 (0.44) | HPGDALDH1A1MAPTKDM4ECYP1A2 | |
| SCHEMBL1827508 | 0.76 | GRM5 (0.43) | LMNAHPGDSMN1; SMN2ALOX15NQO2 | |
| SCHEMBL443476 | 0.74 | HTR1B (0.51) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL411657 | 0.74 | CYP1A2 (0.45) | LMNAHPGDSMN1; SMN2NQO2POLB | |
| SCHEMBL444712 | 0.71 | MCHR1 (0.39) | — | |
| SCHEMBL5751117 | 0.71 | TNKS2 (0.40) | HPGDSMN1; SMN2ALDH1A1MAPTKDM4E | |
| SCHEMBL1146962 | 0.69 | NCF1 (0.47) | LMNAHPGDSMN1; SMN2NQO2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110311649-A1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION, INC. (US) | 2011-12-22 | — | — | US | claimed |
| US-20110224252-A1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION, INC. (US) | 2011-09-15 | — | — | US | claimed |
| EP-2201001-B1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-09-14 | — | — | EP | claimed |
| EP-2201000-B1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-08-31 | — | — | EP | claimed |
| EP-2274285-A1 | NOVEL PYRAZOLE DERIVATIVES | Syngenta Participations AG (CH) | 2011-01-19 | — | — | EP | claimed |
| EP-2201000-A1 | NOVEL IMIDAZOLE DERIVATIVES | Syngenta Participations AG (CH) | 2010-06-30 | — | — | EP | claimed |
| EP-2201001-A1 | NOVEL IMIDAZOLE DERIVATIVES | Syngenta Participations AG (CH) | 2010-06-30 | — | — | EP | claimed |
| WO-2009127612-A1 | NOVEL PYRAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-10-22 | — | — | WO | claimed |
| WO-2009053101-A1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-04-30 | — | — | WO | claimed |
| WO-2009053102-A1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-04-30 | — | — | WO | claimed |
| WO-2003103677-A1 | DERIVATIVES OF AZEPINE AND THIAZERAN AS INTERLEUKIN CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-12-18 | — | — | WO | claimed |
| WO-2003104231-A1 | NOVEL INTERLEUKIN-1β CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-12-18 | — | — | WO | claimed |
| US-20020165222-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-11-07 | — | — | US | claimed |
| WO-2002048102-A2 | ISOCOUMARIN INHIBITING PRODUCTION OF AMYLOID PEPTIDE, PREPARATION, COMPOSITIONS CONTAINING SAME AND USES | TROPHOS (FR) | 2002-06-20 | — | — | WO | claimed |
| EP-1153022-A4 | PROTHEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-03-27 | — | — | EP | claimed |
| EP-1153022-A1 | PROTHEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-14 | — | — | EP | claimed |
| WO-2000049011-A1 | PROTHEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-24 | — | — | WO | claimed |
| EP-0827507-B1 | PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES | BOEHRINGER INGELHEIM CA LTD (CA) | 1999-06-16 | — | — | EP | claimed |
| EP-0827507-A1 | PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1998-03-11 | — | — | EP | claimed |
| WO-1996031527-A1 | PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES | BOEHRINGER INGELHEIM (CANADA) LTD./BOEHRINGER INGELHEIM (CANADA) LTÉE. (CA) | 1996-10-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311649-A1 | NOVEL IMIDAZOLE DERIVATIVES | CBR3, C3AR1, C1R | LMNA 4269/4885HPGD 2618/4885SMN1; SMN2 4859/4885 |
| US-20110224252-A1 | NOVEL IMIDAZOLE DERIVATIVES | C1R, CBR3, C3AR1 | LMNA 3866/4885HPGD 1863/4885SMN1; SMN2 4859/4885 |
| US-20020165222-A1 | Protease inhibitors | CTSK, CTSZ, CTSE | LMNA 2593/4885HPGD 496/4885SMN1; SMN2 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.